M. Stoltz

Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.

G. Schwartz, L. Saltz, Sunil Sharma, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

P. Maslak, J. Werner, G. Schwartz, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pilot pharmacokinetic study of oral azacitidine

H. Kantarjian, G. Garcia-Manero, M. Ward, 2008, Leukemia.

Phase I clinical trials of tezacitabine [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors.

E. Orenberg, Richard E. Jones, G. Rodriguez, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion.

V. Devita, B. Burtness, J. Marsh, 2000, Cancer journal.

An oral dosage formulation of azacitidine: A pilot pharmacokinetic study

M. Ward, J. Etter, G. G. Manero, 2007 .

Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial

S. Weir, M. Stoltz, Donald Reynolds, 1995, Clinical pharmacology and therapeutics.

Pharmacokinetics, pharmacodynamics, and tolerance of single‐ and multiple‐dose fexofenadine hydrochloride in healthy male volunteers

S. Weir, Tanya L. Russell, M. Stoltz, 1998, Clinical pharmacology and therapeutics.

Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A).

M. Eller, S. Weir, D. Yu, 1997, Biopharmaceutics & drug disposition.